

# CLINICAL PHARMACOLOGY & THERAPEUTICS

## EDITOR

Marcus M. Reidenberg, M.D.

## EDITOR EMERITUS

Walter Modell, M.D.

## MANAGING EDITOR

June Reidenberg

## EDITORIAL BOARD

Darrell R. Abernethy, M.D., Ph.D.

Alvito P. Alvares, Ph.D.

Daniel L. Azarnoff, M.D.

William M. Bennett, M.D.

Leif Bertilsson, Ph.D.

Joseph R. Bianchine, M.D., Ph.D.

Thorir D. Bjornsson, M.D.

Terrence F. Blaschke, M.D.

R. A. Branch, M.D.

D. Craig Brater, M.D.

Alastair Breckenridge, M.Sc., M.D.

Paul Calabresi, M.D.

Donald B. Calne, M.D.

Edward A. Carr, Jr., M.D.

Robert J. Cody, Jr., M.D.

Allan H. Conney, Ph.D.

T. S. Danowski, M.D.

Peter Dineen, M.D.

Colin Dollery, M.B., Ch.B., B.Sc.

Edward F. Domino, M.D.

Dennis E. Drayer, Ph.D.

Toby R. Engel, M.D.

Alvan R. Feinstein, M.D.

Robert B. Forney, Ph.D.

Emil Frei III, M.D.

Kathleen Giacomini, Ph.D.

Milo Gibaldi, Ph.D.

Perry V. Halushka, Ph.D., M.D.

Arthur Hull Hayes, Jr., M.D.

Thomas Henthorn, M.D.

Leonard Horowitz, M.D.

Aryeh Hurwitz, M.D.

Harold D. Itskovitz, M.D.

Murray E. Jarvik, M.D.

William J. Jusko, Ph.D.

Anthony Kales, M.D.

Werner Kalow, M.D.

## ASSOCIATE EDITORS

Arthur J. Atkinson, Jr., M.D.

Paul D. Stolley, M.D., M.P.H.

Raymond L. Woosley, M.D., Ph.D.

Stanley A. Kaplan, Ph.D.

Arthur S. Keats, M.D.

Henn Kutt, M.D.

Louis Lasagna, M.D.

Juan J. L. Lertora, M.D., Ph.D.

Paul S. Lietman, M.D., Ph.D.

Louis Lemberger, M.D., Ph.D.

Gerhard Levy, Pharm.D.

T. A. Loomis, M.D., Ph.D.

David T. Lowenthal, M.D.

Robert H. McDonald, Jr., M.D.

Urs A. Meyer, M.D.

Jerry R. Mitchell, M.D., Ph.D.

Arno G. Motulsky, M.D.

Allen H. Neims, M.D., Ph.D.

Harold C. Neu, M.D.

David W. Nierenberg, M.D.

Alan S. Nies, M.D.

George D. Olsen, M.D.

Carl C. Peck, M.D.

William Z. Potter, M.D., Ph.D.

Lawrence G. Raisz, M.D.

David Robertson, M.D.

Lewis B. Sheiner, M.D.

Daniel S. Sitar, Ph.D.

Folke Sjoqvist, M.D.

Craig R. Smith, M.D.

Reynold Spector, M.D.

Donald R. Stanski, M.D.

Robert Temple, M.D.

Leroy D. Vandam, M.D.

Elliot S. Vesell, M.D.

Robert E. Vestal, M.D.

John G. Wagner, Ph.D.

Richard Weinshilboum, M.D.

Thomas L. Whitsett, M.D.

Grant R. Wilkinson, Ph.D.

Alastair J. J. Wood, M.B.Ch.B.

VOLUME 39, JANUARY-JUNE 1986

THE C. V. MOSBY COMPANY, ST. LOUIS

L  
9  
36

Volume 39  
Copyright © 1986 by  
The C. V. Mosby Company

*All rights reserved*

*Printed in the United States of America*

I

# Index to volume 39

## Author index

### A

- Abromowitch M (see Crom et al). 1986; 39:592-7  
 Abshagen U (see Möllendorff et al). 1986; 39:677-82  
 Achari R (see Turlapaty et al). 1986; 39:543-9  
 Ahmad D (see Wilcox et al). 1986; 39:29-34  
 Akpan W (see Möllendorff et al). 1986; 39:677-82  
 Albengres E (see Urien et al). 1986; 39:683-9  
 Albert KS (see Pearson et al). 1986; 39:318-24  
 Allison SJ (see Shader et al). 1986; 39:526-9  
 Altenbern D (see Woosley et al). 1986; 39:282-7  
 Ambre JJ (see Greenberger et al). 1986; 39:163-8  
 Anderson KE, Simionatto CS, Drummond GS, Kappas A: Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans. 1986; 39:510-20  
 Anderson SA (see Brater et al). 1986; 39:631-4  
 Anslow JA (see Greene et al). 1986; 39:300-5  
 Antal EJ (see Grasel Jr et al). 1986; 39:605-12  
 — (see Pearson et al). 1986; 39:318-24  
 Aronoff GR (see Luft et al). 1986; 39:414-9  
 Asinger R (see Pentel et al). 1986; 39:102-3 (Letter reply)  
 Atkinson AJ Jr (see Greenberger et al). 1986; 39:163-8  
 Austin B (see Israel et al). 1986; 39:261-4

### B

- Barth JT (see Minocha et al). 1986; 39:123-7  
 Bawdon RE (see Brater et al). 1986; 39:631-4  
 Beach CA, Mays DC, Guiler RC, Jacober CH, Gerber N: Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. 1986; 39:265-70  
 Bell V (see Turlapaty et al). 1986; 39:543-9  
 Bellucci A (see Israel et al). 1986; 39:261-4  
 Belz GG, Wistuba S, Matthews JH: Digoxin and bepridil: Pharmacokinetic and pharmacodynamic interactions. 1986; 39:65-71  
 Benet LZ (see Legler and Benet). 1986; 39:425-9  
 Benowitz N (see Pentel et al). 1986; 39:102-3 (Letter reply)  
 Berardi RR (see Lau et al). 1986; 39:635-45  
 Berger LG (see Montgomery et al). 1986; 39:571-6  
 Berkowitz LR (see Orringer et al). 1986; 39:276-81  
 Bertilsson L (see Mellström et al). 1986; 39:369-71  
 Bertino JS Jr (see Dickson et al). 1986; 39:325-8  
 Bing-Wen W (see Morgan et al). 1986; 39:102 (Letter)  
 Birkett DJ (see Lelo et al). 1986; 39:54-9  
 Bischoff AK (see Joss et al). 1986; 39:619-24  
 Bixler EO (see Kales et al). 1986; 39:345-52  
 Bjerg-Nielsen A (see Duus et al). 1986; 39:342-4  
 Björnsson TD, Huang AT, Roth P, Jacob DS, Christenson R: Effect of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations. 1986; 39:25-8  
 Bloedow DC (see Zachariah et al). 1986; 39:586-91  
 Bouthier JA, Safar ME, Curien ND, London GM, Levenson JA, Simon AC: Effect of cadralazine on brachial artery hemodynamics and forearm venous tone in essential hypertension. 1986; 39:82-8

- (see Maarek et al). 1986; 39:403-8  
 Branch RA (see Jacqz et al). 1986; 39:646-53  
 Brass C (see Glynn et al). 1986; 39:654-9  
 Brater DC, Bawdon RE, Anderson SA, Purdue GF, Hunt JL: Vancomycin elimination in patients with burn injury. 1986; 39:631-4  
 Breckenridge AM (see Nies and Breckenridge). 1986; 39:466-70 (Symposium)  
 Brown RS (see Williams et al). 1986; 39:420-4  
 Brunner HR (see Busse et al). 1986; 39:554-8  
 Brunner KW (see Joss et al). 1986; 39:619-24  
 Bryant PJ (see Culbertson et al). 1986; 39:690-6  
 Budnitz E (see Johnson et al). 1986; 39:306-12  
 Bullingham RES (see McQuay et al). 1986; 39:89-93  
 Burckart GJ (see Mehta et al). 1986; 39:372-7  
 Burge J (see Turlapaty et al). 1986; 39:543-9  
 Burns RJ (see Esquivel et al). 1986; 39:395-402  
 — (see Myers et al). 1986; 39:409-13  
 Busse J-P, d'Amore TF, Perret L, Porchet M, Nussberger J, Waeber B, Brunner HR: Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. 1986; 39:554-8  
 Byrne LM (see Weintraub et al). 1986; 39:501-9  
 Byyny RL (see Culbertson et al). 1986; 39:690-6

### C

- Cady WJ (see Culbertson et al). 1986; 39:690-6  
 Carroll D (see McQuay et al). 1986; 39:89-93  
 Carruthers SG (see Wilcox et al). 1986; 39:29-34  
 Chang CW (see Lau et al). 1986; 39:151-5  
 Chow MJ (see Greenberger et al). 1986; 39:163-8  
 Christensen S (see Duus et al). 1986; 39:342-4  
 Christenson R (see Björnsson et al). 1986; 39:25-8  
 Cinquegrani MP, Liang C-s: Indomethacin attenuates the hypotensive action of hydralazine. 1986; 39:564-70  
 Clementy J (see Wicker and Clementy). 1986; 39:537-42  
 Cody RJ, Kubo SH, Covit AB, Müller FB, Rutman H, Leonard D, Laragh JH, Feldschuh J, Preibisz J: Regional blood flow and neurohormonal responses to milrinone in congestive heart failure. 1986; 39:128-35  
 Conrad KA (see Fagan et al). 1986; 39:255-60  
 — (see Johnson et al). 1986; 39:697-702  
 Coumel P (see Escoubet et al). 1986; 39:361-8  
 Covit AB (see Cody et al). 1986; 39:128-35  
 Coyle DE, Denson DD, Essell SK, Santos DJ: The effect of nonesterified fatty acids and progesterone on bupivacaine protein binding. 1986; 39:559-63  
 Craig WA (see Pearson et al). 1986; 39:318-24  
 Crom WR, Glynn AM, Abromowitch M, Pui C-H, Dodge R, Evans WE: Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance. 1986; 39:592-7  
 Cross RE (see Orringer et al). 1986; 39:276-81  
 Crout JR: A description of clinical pharmacology and the clinical pharmacologist. 1986; 39:439 (Symposium)  
 — (see Peck and Crout). 1986; 39:451-8 (Symposium)

- Culbertson VL, Bryant PJ, Cady WJ, Rubison RM, Piepho RW, Nies AS, Byyny RL: Acute effects of increasing doses of urapidil in patients with hypertension. 1986; 39:690-6  
Curien ND (see Bouthier et al). 1986; 39:82-8

## D

- Dai G (see Woosley et al). 1986; 39:282-7  
d'Amore TF (see Bussein et al). 1986; 39:554-8  
Darke AC (see Wilcox et al). 1986; 39:29-34  
Dawe M (see Gault et al). 1986; 39:530-6  
D'Ambrosio R (see Glynn et al). 1986; 39:654-9  
De Blasi A, Lipartiti M, Pirone F, Rochat C, Prost J-F, Garattini S: Reduction of beta-adrenergic receptors by tertatolol: An additional mechanism for beta-adrenergic blockade. 1986; 39:245-54  
de Boo T (see Lenders et al). 1986; 39:353-7  
de Wolff FA (see Edelbroek et al). 1986; 39:156-62  
Delhotal-Landes B (see Escoubet et al). 1986; 39:361-8  
Denson DD (see Coyle et al). 1986; 39:559-63  
Derendorf H, Möllmann H, Grüner A, Haack D, Gyselby G: Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. 1986; 39:313-7  
Dickson CJ, Schwartzman MS, Bertino JS Jr: Factors affecting aminoglycoside disposition: Effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics. 1986; 39:325-8  
Dixon R, Howes J, Gentile J, Hsu H-B, Hsiao J, Garg D, Weidler D, Meyer M, Tuttle R: Nalmefene: Intravenous safety and kinetics of a new opioid antagonist. 1986; 39:49-53  
Dodge R (see Crom et al). 1986; 39:592-7  
Dohrmann M (see Kuhlmann et al). 1986; 39:288-94  
Dollery CT: The public need for clinical pharmacology in the United Kingdom. 1986; 39:440-2 (Symposium)  
Donnelly M, Zametkin AJ, Rapoport JL, Ismond DR, Weingartner H, Lane E, Oliver J, Linnola M, Potter WZ: Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. 1986; 39:72-81  
Donohue JF (see Kelly et al). 1986; 39:577-81  
Dreyfuss D (see Shader et al). 1986; 39:526-9  
Drummond GS (see Anderson et al). 1986; 39:510-20  
Duus BR, Hølmich P, Larsen CT, Wille-Jørgensen, Bjerg-Nielsen A, Christensen S: Dihydroergotamine and mobilization after major orthopedic surgery. 1986; 39:342-4  
Dylewicz P (see Kirch et al). 1986; 39:35-9

## E

- Edelbroek PM, Linssen CG, Zitman FG, Rooymans HGM, de Wolff FA: Analgesic and antidepressive effects of low-dose amitriptyline in relation to its metabolism in patients with chronic pain. 1986; 39:156-62  
Eichler HG (see Gasic et al). 1986; 39:582-5  
Ellis NF, MacGillivray MH, Voorhess ML: Effect of clonidine on plasma cortisol concentrations. 1986; 39:660-3  
Endele R (see Patschke et al). 1986; 39:145-50  
Escoubet B, Leclercq J-F, Maison-Blanche P, Poirier J-M, Gourmel B, Delhotal-Landes B, Coumel P: Comparison of four beta-blockers as assessed by 24-hour ECG recording. 1986; 39:361-8  
Esquivel M, Burns RJ, Ogilvie RI: Cardiovascular effects of enprofylline and theophylline. 1986; 39:395-402  
Essell SK (see Coyle et al). 1986; 39:559-63  
Evans WE (see Crom et al). 1986; 39:592-7

## F

- Fagan TC, Conrad KA, Mar JH, Nelson L: Effects of meals on hemodynamics: Implications for antihypertensive drug studies. 1986; 39:255-60  
Fealey RD (see Zachariah et al). 1986; 39:586-91  
Feldschuh J (see Cody et al). 1986; 39:128-35

- Fineberg NS (see Luft et al). 1986; 39:414-9  
Frais MA (see Silke et al). 1986; 39:5-14  
Frankel D (see Myers et al). 1986; 39:409-13  
Freis ED: The cardiovascular risks of thiazide diuretics. 1986; 39:239-44 (Commentary)  
Frisk-Holmberg M, Wibell L: Concentration-dependent blood pressure effects of guanfacine. 1986; 39:169-72

## G

- Galeazzi RL (see Joss et al). 1986; 39:619-24  
Gall HE (see Vermorken et al). 1986; 39:136-44  
Garattini S (see De Blasi et al). 1986; 39:245-54  
Garg D (see Dixon et al). 1986; 39:49-53  
— (see Scatina et al). 1986; 39:550-3  
Gasic S, Korn A, Eichler HG: Effect of diclofenac, a novel antidepressant, on peripheral adrenergic function. 1986; 39:582-5  
Gault H, Vasdev S, Vlases P, Longrich L, Dawe M: Interpretation of serum digoxin values in renal failure. 1986; 39:530-6  
Gentile J (see Dixon et al). 1986; 39:49-53  
Gerber N (see Beach et al). 1986; 39:265-70  
Gerrein JR (see Shader et al). 1986; 39:526-9  
Geyskes GG (see van Schaik et al). 1986; 39:60-4  
Ghoneim MM, Hinrichs JV, Mewaldt SP: Comparison of two benzodiazepines with differing accumulation: Behavioral changes during and after 3 weeks of dosing. 1986; 39:491-500  
Gibaldi M (see Toon et al). 1986; 39:15-24  
Gideon DA (see Minocha et al). 1986; 39:123-7  
Ginsberg G (see Weintraub et al). 1986; 39:501-9  
Glynn AM, Slaughter RL, Brass C, D'Ambrosio R, Jusko WJ: Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. 1986; 39:654-9  
— (see Crom et al). 1986; 39:592-7  
Goldenheim PD: No "dose-dumping" with once-a-day Uniphyll. 1986; 39:598 (Letter)  
Goldlust MB (see Williams et al). 1986; 39:420-4  
Gorodetzky CW (see Yeh et al). 1986; 39:669-76  
Gorsch HK (see Pearson et al). 1986; 39:318-24  
Goulart DA (see Toon et al). 1986; 39:15-24  
Gourmel B (see Escoubet et al). 1986; 39:361-8  
Gräf KJ (see Kirch et al). 1986; 39:35-9  
Grahame-Smith DG (see Mitchell and Grahame-Smith). 1986; 39:471-3 (Symposium)  
Grasela TH Jr, Antal EJ, Townsend RJ, Smith RB: An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies. 1986; 39:605-12  
Gray JA (see Mehta et al). 1986; 39:372-7  
Greenberger PA, Chow MJ, Atkinson AJ Jr, Ambre JJ, Patterson R: Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. 1986; 39:163-8  
Greenblatt DJ (see Shader et al). 1986; 39:526-9  
Greene DS, Szego PL, Anslow JA, Hooper JW: The effect of age on ranitidine pharmacokinetics. 1986; 39:300-5  
Griffin VL (see Williams et al). 1986; 39:420-4  
Grüner A (see Derendorf et al). 1986; 39:313-7  
Guiler RC (see Beach et al). 1986; 39:265-70  
Gyselby G (see Derendorf et al). 1986; 39:313-7

## H

- Haack D (see Derendorf et al). 1986; 39:313-7  
Hager WD (see White et al). 1986; 39:664-8  
Hall SD (see Jacqz et al). 1986; 39:646-53  
Harmatz JS (see Shader et al). 1986; 39:526-9  
Harrison LI (see Williams et al). 1986; 39:420-4  
Hart GAM (see Vermorken et al). 1986; 39:136-44  
Henningfield JE (see Nemeth-Coslett and Henningfield). 1986; 39:625-30  
Herold DA (see Minocha et al). 1986; 39:123-7

- Hibbard DM (see Hunninghake and Hibbard). 1986; 39:329-34  
Hicks D (see Scatina et al). 1986; 39:550-3  
Hinrichs JV (see Ghoneim et al). 1986; 39:491-500  
Hölmich P (see Duus et al). 1986; 39:342-4  
Hooper JW (see Greene et al). 1986; 39:300-5  
Howes J (see Dixon et al). 1986; 39:49-53  
Hsiao J (see Dixon et al). 1986; 39:49-53  
Hsu H-B (see Dixon et al). 1986; 39:49-53  
Huang AT (see Björnsson et al). 1986; 39:25-8  
Hulse J (see Turlapaty et al). 1986; 39:543-9  
Hunninghake DB, Hibbard DM: Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide. 1986; 39:329-34  
Hunt JL (see Brater et al). 1986; 39:631-4  
Hutt HJ (see Kirch et al). 1986; 39:35-9  
Hyneck ML (see Lau et al). 1986; 39:635-45

# I

- Ismond DR (see Donnelly et al). 1986; 39:72-81  
Israel R, O'Mara V, Austin B, Bellucci A, Meyer BR: Metoclopramide decreases renal plasma flow. 1986; 39:261-4

# J

- Jacob DS (see Björnsson et al). 1986; 39:25-8  
Jacobson CH (see Beach et al). 1986; 39:265-70  
Jacoby JA (see Kales et al). 1986; 39:345-52  
Jacqz E, Hall SD, Branch RA, Wilkinson GR: Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co-regulated substrate, mephobarbital. 1986; 39:646-53  
Jain AK, Ryan JR, McMahon FG, Smith G: Comparison of oral nalbuphine, acetaminophen, and their combination in postoperative pain. 1986; 39:295-9  
Johnsen J (see Stowell et al). 1986; 39:521-5  
Johnson BF, Lindenbaum J, Budnitz E, Marwaha R: Variability of steady-state digoxin kinetics during administration of tablets or capsules. 1986; 39:306-12  
—, Romero L, Marwaha R: Hemodynamic and metabolic effects of the calcium channel blocking agent nitrendipine. 1986; 39:389-94  
Johnson RE (see Yeh et al). 1986; 39:669-76  
Johnson SL, Mayersohn M, Conrad KA: Xylose disposition as a function of age. 1986; 39:697-702  
Jones JK (see Strom et al). 1986; 39:335-41  
Joss RA, Galeazzi RL, Bischoff AK, Pirovino M, Ryssel HJ, Brunner KW: The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: A prospective, randomized, double-blind trial. 1986; 39:619-24  
Jusko WJ (see Glynn et al). 1986; 39:654-9

# K

- Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby JA, Kales JD: Quazepam and temazepam: Effects of short- and intermediate-term use and withdrawal. 1986; 39:345-52  
Kales JD (see Kales et al). 1986; 39:345-52  
Kalman CM (see Stahl-Bayliss et al). 1986; 39:271-5  
Kappas A (see Anderson et al). 1986; 39:510-20  
Karim A: No "dose-dumping" with once-a-day Uniphyl. 1986; 39:598-9 (Letter reply)  
Kaufmann B (see Patscheke et al). 1986; 39:145-50  
Kelly HW, Powell JR, Donohue JF: Ranitidine at very large doses does not inhibit theophylline elimination. 1986; 39:577-81  
Kirch W, Hutt HJ, Dylewicz P, Gräf KJ, Ohnhaus EE: Dose-dependence of the nifedipine-digoxin interaction. 1986; 39:35-9  
Kirksey D (see Ryan et al). 1986; 39:40-2  
Klein I (see Vermorken et al). 1986; 39:136-44  
Korn A (see Gasić et al). 1986; 39:582-5  
Kraml M (see Scatina et al). 1986; 39:550-3

- Kubo SH (see Cody et al). 1986; 39:128-35  
Kuhlmann J, Dohrmann M, Marcin S: Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. 1986; 39:288-94

# L

- Laddu A (see Turlapaty et al). 1986; 39:543-9  
Lane E (see Donnelly et al). 1986; 39:72-81  
Lane TJ (see White et al). 1986; 39:43-8  
Lange WR (see Yeh et al). 1986; 39:669-76  
Laragh JH (see Cody et al). 1986; 39:128-35  
Larsen CT (see Duus et al). 1986; 39:342-4  
Laskin OL (see Stahl-Bayliss et al). 1986; 39:271-5  
Lau AH, Chang CW, Schlesinger PK: Evaluation of a potential drug interaction between sucralfate and aspirin. 1986; 39:151-5  
Lau HSH, Hyneck ML, Berardi RR, Swartz RD, Smith DE: Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure. 1986; 39:635-45  
Lazar EL (see Strom et al). 1986; 39:335-41  
Leclercq J-F (see Escoubet et al). 1986; 39:361-8  
Leenen FHH (see Myers et al). 1986; 39:409-13  
Legler UF, Benet LZ: Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives. 1986; 39:425-9  
Leighton J (see Ryan et al). 1986; 39:40-2  
Lelo A, Miners JO, Robson R, Birkett KJ: Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. 1986; 39:54-9  
Lemberger L: From "grass" roots to clinical utility. 1986; 39:1-4 (Commentary)  
—, Rawlins MD: Workshop report: Fiscal support. 1986; 39:477-80 (Symposium)  
Lemmens WAJ (see Lenders et al). 1986; 39:353-7  
Lenders JWM, Salemans J, de Boo T, Lemmens WAJ, Thien T, van't Laar A: The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects. 1986; 39:353-7  
Leonard D (see Cody et al). 1986; 39:128-35  
Levenson JA (see Bouthier et al). 1986; 39:82-8  
— (see Maarek et al). 1986; 39:403-8  
Liang C-s (see Cinquegrani and Liang). 1986; 39:564-70  
Lindberg RLP, Syvälahti EKG: Metabolism of nomifensine after oral and intravenous administration. 1986; 39:378-83  
—, —, Pihlajamäki KK: Disposition of nomifensine after acute and prolonged dosing. 1986; 39:384-8  
Lindenbaum J (see Johnson et al). 1986; 39:306-12  
Linnoila M (see Donnelly et al). 1986; 39:72-81  
Linssen CG (see Edelbroek et al). 1986; 39:156-62  
Lipartiti M (see De Blasi et al). 1986; 39:245-54  
London GM (see Bouthier et al). 1986; 39:82-8  
Longerich L (see Gault et al). 1986; 39:530-6  
Low LK (see Toon et al). 1986; 39:15-24  
Luft FC, Aronoff GR, Sloan RS, Fineberg NS, Weinberger MH: Short-term augmented calcium intake has no effect on sodium homeostasis. 1986; 39:414-9

# M

- Maarek B, Simon ACh, Levenson J, Merli I, Bouthier J: Chronic effects of pindolol on the arterioles, large arteries, and veins of the forearm in mild to moderate essential hypertension. 1986; 39:403-8  
MacGillivray MH (see Ellis et al). 1986; 39:660-3  
Maison-Blanche P (see Escoubet et al). 1986; 39:361-8  
Mar JH (see Fagan et al). 1986; 39:255-60  
Marcin S (see Kuhlmann et al). 1986; 39:288-94  
Marwaha R (see Johnson et al). 1986; 39:306-12, 389-94

- Matthews JH (see Belz et al). 1986; 39:65-71  
 Mayersohn M (see Johnson et al). 1986; 39:697-702  
 Mays DC (see Beach et al). 1986; 39:265-70  
 McCabe EJ (see White et al). 1986; 39:664-8  
 McDevitt DG: Clinical pharmacologists for the future in the United Kingdom. 1986; 39:459-61 (Symposium)  
 McMahon FG (see Jain et al). 1986; 39:295-9  
 McMahon G (see Ryan et al). 1986; 39:40-2  
 McQuay HJ, Poppleton P, Carroll D, Summerfield RJ, Bullingham RES, Moore RA: Ketorolac and acetaminophen for orthopedic postoperative pain. 1986; 39:89-93  
 Mees EJD (see van Schaik et al). 1986; 39:60-4  
 Mehta MU, Venkataramanan R, Burckart GJ, Ptachcinski RJ, Yang SL, Gray JA, Van Thiel DH, Starzl TE: Antipyrine kinetics in liver disease and liver transplantation. 1986; 39:372-7  
 Mellström, Säwe J, Bertilsson L, Sjöqvist F: Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers. 1986; 39:369-71  
 Melmon KL: The public need for clinical pharmacology in the United States. 1986; 39:443-7 (Symposium)  
 Merli I (see Maarek et al). 1986; 39:403-8  
 Mewaldt SP (see Ghoneim et al). 1986; 39:491-500  
 Meyer BR (see Israel et al). 1986; 39:261-4  
 Meyer M (see Dixon et al). 1986; 39:49-53  
 Miners JO (see Lelo et al). 1986; 39:54-9  
 Minocha A, Barth JT, Herold DA, Gideon DA, Spyker DA: Modulation of ethanol-induced central nervous system depression by ibuprofen. 1986; 39:123-7  
 Mitchell JR, Grahame-Smith DG: Workshop report: Academic pursuits in clinical pharmacology. Research emphasis. 1986; 39:471-3 (Symposium)  
 Mitenko PA (see Montgomery et al). 1986; 39:571-6  
 Möllendorff EV, Abshagen U, Akpan W, Neugebauer G, Schröter E: Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity. 1986; 39:677-82  
 Möllmann H (see Derendorf et al). 1986; 39:313-7  
 Montgomery PR, Berger LG, Mitenko PA, Sitar DS: Salicylate metabolism: Effects of age and sex in adults. 1986; 39:571-6  
 Moore RA (see McQuay et al). 1986; 39:89-93  
 Morgan JP, Puder KS, Bing-Wen W: Phenylpropanolamine and blood pressure. 1986; 39:102 (Letter)  
 Mørland J (see Stowell et al). 1986; 39:521-5  
 Morse ML (see Strom et al). 1986; 39:335-41  
 Mosberg H (see Turlapaty et al). 1986; 39:543-9  
 Motley CH (see Toon et al). 1986; 39:15-24  
 Moyer TP (see Zachariah et al). 1986; 39:586-91  
 Müller FB (see Cody et al). 1986; 39:128-35  
 Myers MG, Leenen FHH, Burns R, Frankel D: Nifedipine tablet vs. hydralazine in patients with persisting hypertension who receive combined diuretic and beta-blocker therapy. 1986; 39:409-13

## N

- Nelson L (see Fagan et al). 1986; 39:255-60  
 Nemeth-Coslett R, Henningfield JE: Effects of nicotine chewing gum on cigarette smoking and subjective and physiologic effects. 1986; 39:625-30  
 Neugebauer G (see Möllendorff et al). 1986; 39:677-82  
 — (see Patschke et al). 1986; 39:145-50  
 Ng K-T (see Orringer et al). 1986; 39:276-81  
 Nies AS: Prostaglandins and the control of the circulation. 1986; 39:481-8 (Commentary)  
 —, Breckenridge AM: Workshop report: Clinical pharmacology teaching, training and career development. 1986; 39:466-70 (Symposium)  
 — (see Culbertson et al). 1986; 39:690-6  
 Nussberger J (see Bussein et al). 1986; 39:554-8

## O

- Oates JA: Clinical pharmacologists for the future in the United States. 1986; 39:462-5 (Symposium)  
 — (see Woosley et al). 1986; 39:282-7  
 O'Connor P (see Weintraub et al). 1986; 39:501-9  
 Ogilvie RI (see Esquivel et al). 1986; 39:395-402  
 Ohnhaus EE (see Kirch et al). 1986; 39:35-9  
 Oliver J (see Donnelly et al). 1986; 39:72-81  
 O'Mara V (see Israel et al). 1986; 39:261-4  
 O'Reilly RA (see Toon et al). 1986; 39:15-24  
 Orringer EP, Powell R, Cross RE, Rogers JF, Wojcieszyn O, Phillips JC, Reed J, Ng K-T, Berkowitz LR: A single-dose pharmacokinetic study of the antisickling agent cetiedil. 1986; 39:276-81

## P

- Parsons J (see Wilcox et al). 1986; 39:29-34  
 Patschke H, Staiger C, Neugebauer G, Kaufmann B, Strein K, Ende R, Stegmeier K: The pharmacokinetic and pharmacodynamic profiles of the thromboxane A<sub>2</sub> receptor blocker BM 13.177. 1986; 39:145-50  
 Patterson R (see Greenberger et al). 1986; 39:163-8  
 Pearson JG, Antal EJ, Raehl CL, Gorsch HK, Craig WA, Albert KS, Welling PG: Pharmacokinetic disposition of <sup>14</sup>C-glyburide in patients with varying renal function. 1986; 39:318-24  
 Peck CC, Crout JR: Current status of clinical pharmacology training in the United States. 1986; 39:451-8 (Symposium)  
 Pentel P, Asinger R, Benowitz N: Phenylpropanolamine and blood pressure. 1986; 39:102-3 (Letter reply)  
 Perret L (see Bussein et al). 1986; 39:554-8  
 Petrie JC, Reidenberg MM: Workshop report: Health care and patient services. 1986; 39:474-6 (Symposium)  
 Phillips JC (see Orringer et al). 1986; 39:276-81  
 Piepho RW (see Culbertson et al). 1986; 39:690-6  
 Pihlajamäki KK (see Lindberg et al). 1986; 39:384-8  
 Pinedo HM (see Vermorken et al). 1986; 39:136-44  
 Pinquier J-L (see Urien et al). 1986; 39:683-9  
 Pirone F (see De Blasi et al). 1986; 39:245-54  
 Pirovino M (see Joss et al). 1986; 39:619-24  
 Podesla S (see White et al). 1986; 39:43-8  
 Poirier J-M (see Escoubet et al). 1986; 39:361-8  
 Poppleton P (see McQuay et al). 1986; 39:89-93  
 Porchet M (see Bussein et al). 1986; 39:554-8  
 Potter WZ (see Donnelly et al). 1986; 39:72-81  
 Powell JR (see Kelly et al). 1986; 39:577-81  
 Powell R (see Orringer et al). 1986; 39:276-81  
 Preibisz J (see Cody et al). 1986; 39:128-35  
 Prost J-F (see De Blasi et al). 1986; 39:245-54  
 Ptachcinski RJ (see Mehta et al). 1986; 39:372-7  
 Puder KS (see Morgan et al). 1986; 39:102 (Letter)  
 Pui C-H (see Crom et al). 1986; 39:592-7  
 Purdue GF (see Brater et al). 1986; 39:631-4

## R

- Raehl CL (see Pearson et al). 1986; 39:318-24  
 Rapoport JL (see Donnelly et al). 1986; 39:72-81  
 Rawlins MD (see Lemberger and Rawlins). 1986; 39:477-80 (Symposium)  
 Reed J (see Orringer et al). 1986; 39:276-81  
 Reidenberg MM (see Petrie and Reidenberg). 1986; 39:474-6 (Symposium)  
 Reynolds G (see Silke et al). 1986; 39:5-14  
 Ripel A (see Stowell et al). 1986; 39:521-5  
 Robson R (see Lelo et al). 1986; 39:54-9

- Rochat C (see De Biasi et al). 1986; 39:245-54  
Roden DM (see Woosley et al). 1986; 39:282-7  
Rogers JF (see Orringer et al). 1986; 39:276-81  
Romero L (see Johnson et al). 1986; 39:389-94  
Roos JC (see van Schaik et al). 1986; 39:60-4  
Rooymans HGM (see Edelbroek et al). 1986; 39:156-62  
Rosa RM (see Williams et al). 1986; 39:420-4  
Roth P (see Björnsson et al). 1986; 39:25-8  
Rubinson RM (see Culbertson et al). 1986; 39:690-6  
Rutman H (see Cody et al). 1986; 39:128-35  
Ryan J, Leighton J, Kirksey D, McMahon G: Evaluation of an encephalin analog in men with castor oil-induced diarrhea. 1986; 39:40-2  
Ryan JR (see Jain et al). 1986; 39:295-9  
Rysse HJ (see Joss et al). 1986; 39:619-24

# S

- Safar ME (see Bouthier et al). 1986; 39:82-8  
Salemans J (see Lenders et al). 1986; 39:353-7  
Sanda M (see Scatina et al). 1986; 39:550-3  
Santos DJ (see Coyle et al). 1986; 39:559-63  
Säwe J (see Mellström et al). 1986; 39:369-71  
Scatina J, Hicks D, Kraml M, Weidler D, Garg D, Sanda M: Etodolac kinetics in the elderly. 1986; 39:550-3  
Schirger A (see Zachariah et al). 1986; 39:586-91  
Schlesinger PK (see Lau et al). 1986; 39:151-5  
Schröter E (see Möllendorff et al). 1986; 39:677-82  
Schulman P (see White et al). 1986; 39:664-8  
Schuster B (see Weintraub et al). 1986; 39:501-9  
Schwartzman MS (see Dickson et al). 1986; 39:325-8  
Shader RI, Dreyfuss D, Gerrein JR, Harmatz JS, Allison SJ, Greenblatt DJ: Sedative effects and impaired learning and recall after single oral doses of lorazepam. 1986; 39:526-9  
Shang SF (see Williams et al). 1986; 39:420-4  
Sheps SG (see Zachariah et al). 1986; 39:586-91  
Silke B, Verma SP, Fraiss MA, Reynolds G, Taylor SH: Comparative effects of metoprolol and celiprolol on cardiac hemodynamics and left ventricular volume at rest and during exercise-induced angina. 1986; 39:5-14  
Simionatto CS (see Anderson et al). 1986; 39:510-20  
Simon ACh (see Bouthier et al). 1986; 39:82-8  
—— (see Maarek et al). 1986; 39:403-8  
Sitar DS (see Montgomery et al). 1986; 39:571-6  
Sjöqvist (see Mellström et al). 1986; 39:369-71  
Slaughter RL (see Glynn et al). 1986; 39:654-9  
Sloan RS (see Luft et al). 1986; 39:414-9  
Smith DE (see Lau et al). 1986; 39:635-45  
Smith G (see Jain et al). 1986; 39:295-9  
Smith RB (see Grasela Jr et al). 1986; 39:605-12  
Soldatos CR (see Kales et al). 1986; 39:345-52  
Spyker DA (see Minocchia et al). 1986; 39:123-7  
Stahl-Bayliss C, Kalman CM, Laskin OL: Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome. 1986; 39:271-5  
Staiger C (see Patscheke et al). 1986; 39:145-50  
Starzi TE (see Mehta et al). 1986; 39:372-7  
Stegmeier K (see Patscheke et al). 1986; 39:145-50  
Stein EC (see Weintraub et al). 1986; 39:501-9  
Stolley PD, Strom BL: Sample size calculations for clinical pharmacology studies. 1986; 39:489-90 (Commentary)  
—— (see Strom et al). 1986; 39:335-41  
Stowell A, Johnsen J, Ripel Å, Mørland J: Diphenhydramine and the calcium carbimide-ethanol reaction: A placebo-controlled clinical study. 1986; 39:521-5  
Strein K (see Patscheke et al). 1986; 39:145-50  
Strom BL, Tamragouri RN, Morse ML, Lazar EL, West SL, Stolley

- PD, Jones JK: Oral contraceptives and other risk factors for gallbladder disease. 1986; 39:335-41  
—— (see Stolley and Strom). 1986; 39:489-90 (Commentary)  
Summerfield RJ (see McQuay et al). 1986; 39:89-93  
Sundaresan PR (see Weintraub et al). 1986; 39:501-9  
Swartz RD (see Lau et al). 1986; 39:635-45  
Syvälahti EKG (see Lindberg and Syvälahti). 1986; 39:378-83  
—— (see Lindberg et al). 1986; 39:384-8  
Szego PL (see Greene et al). 1986; 39:300-5

# T

- Tamragouri RN (see Strom et al). 1986; 39:335-41  
Tang Z-M (see Wu et al). 1986; 39:613-8  
Taylor SH (see Silke et al). 1986; 39:5-14  
Thien T (see Lenders et al). 1986; 39:353-7  
Tillement J-P (see Urien et al). 1986; 39:683-9  
Todd GD (see Yeh et al). 1986; 39:669-76  
Toon S, Low LK, Gibaldi M, Trager WF, O'Reilly RA, Motley CH, Goulart DA: The warfarin-sulfinpyrazole interaction: Stereochemical considerations. 1986; 39:15-24  
Townsend RJ (see Grasela Jr et al). 1986; 39:605-12  
Trager WF (see Toon et al). 1986; 39:15-24  
Turlapaty P, Burge J, Hulse J, Achari R, Bell V, Mosberg H, Laddu A: Tolerance and beta-adrenergic blocking activity of flecetolol, a short-acting beta blocker. 1986; 39:543-9  
Turner P: Current status of clinical pharmacology in the United Kingdom. 1986; 39:448-50 (Symposium)  
Tuttle R (see Dixon et al). 1986; 39:49-53

# U

- Urien S, Albengres E, Pinquier J-L, Tillement J-P: Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin. 1986; 39:683-9

# V

- van der Vijgh WJF (see Vermorken et al). 1986; 39:136-44  
van Groenigen CJ (see Vermorken et al). 1986; 39:136-44  
van Schaik BAM, Geyskes GG, Roos JC, Mees EJD: Changes in blood pressure and body fluid volumes during diuretic therapy in patients with essential hypertension who receive enalapril. 1986; 39:60-4  
Van Thiel DH (see Mehta et al). 1986; 39:372-7  
van't Laar A (see Lenders et al). 1986; 39:353-7  
Vasdev S (see Gault et al). 1986; 39:530-6  
Vela-Bueno A (see Kales et al). 1986; 39:345-52  
Venkataramanan R (see Mehta et al). 1986; 39:372-7  
Verma SP (see Silke et al). 1986; 39:5-14  
Vermorken JB, van der Vijgh WJF, Klein I, Gall HE, van Groenigen CJ, Hart GAM, Pinedo HM: Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. 1986; 39:136-44  
Viadero JJ (see White et al). 1986; 39:43-8  
Vlasses P (see Gault et al). 1986; 39:530-6  
Voorhess ML (see Ellis et al). 1986; 39:660-3

# W

- Waeber B (see Bussein et al). 1986; 39:554-8  
Wang M-Z (see Wu et al). 1986; 39:613-8  
Wang T (see Woosley et al). 1986; 39:282-7  
Weidler D (see Dixon et al). 1986; 39:49-53  
—— (see Scatina et al). 1986; 39:550-3  
Weinberger MH (see Luft et al). 1986; 39:414-9  
Weinblatt M (see Williams et al). 1986; 39:420-4

- Weingartner H (see Donnelly et al). 1986; 39:72-81
- Weintraub M, Ginsberg G, Stein EC, Sundaresan PR, Schuster B, O'Connor P, Byrne LM: Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modification. 1986; 39:501-9
- Welling PG (see Pearson et al). 1986; 39:318-24
- West SL (see Strom et al). 1986; 39:335-41
- White WB, Schulman P, McCabe EJ, Hager WD: Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate. 1986; 39:664-8
- , Viadero JJ, Lane TJ, Podesla S: Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. 1986; 39:43-8
- Wibell L (see Frisk-Holmberg and Wibell). 1986; 39:169-72
- Wicker P, Clementy J: Comparison of the effects of muzolimine and a fixed combination of diuretics in essential hypertension. 1986; 39:537-42
- Wilcox PG, Ahmad D, Darke AC, Parsons J, Carruthers SG: Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma. 1986; 39:29-34
- Wilkinson GR (see Jacqz et al). 1986; 39:646-53
- (see Woosley et al). 1986; 39:282-7
- Wille-Jørgensen P (see Duus et al). 1986; 39:342-4
- Williams ME, Weinblatt M, Rosa RM, Griffin VL, Goldlust MB, Shang SF, Harrison LI, Brown RS: Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis. 1986; 39:420-4
- Wilson TW: The antihypertensive action of hydrochlorothiazide and renal prostacyclin. 1986; 39:94-101
- Wistuba S (see Belz et al). 1986; 39:65-71
- Wojcieszyn O (see Orringer et al). 1986; 39:276-81
- Woosley RL, Roden DM, Dai G, Wang T, Altenbern D, Oates J, Wilkinson GR: Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. 1986; 39:282-7
- Wu D-F, Yu Y-W, Tang Z-M, Wang M-Z: Pharmacokinetics of ( $\pm$ )-, (+)-, and (-)-gossypol in humans and dogs. 1986; 39:613-8
- Y**
- Yang SL (see Mehta et al). 1986; 39:372-7
- Yeh SY, Todd GD, Johnson RE, Gorodetzky CW, Lange WR: The pharmacokinetics of pentazocine and tripeleminamine. 1986; 39:669-76
- Yu Y-W (see Wu et al). 1986; 39:613-8
- Z**
- Zachariah PK, Bloedow DC, Moyer TP, Sheps SG, Schirger A, Fealey RD: Pharmacodynamics of midodrine, an antihypotensive agent. 1986; 39:586-91
- Zametkin AJ (see Donnelly et al). 1986; 39:72-81
- Zitman FG (see Edelbroek et al). 1986; 39:156-62

## Subject index

### A

#### Abstracts

Abstracts. 1986; 39:176-238

#### Acetabulol

Comparison of four beta-blockers as assessed by 24-hour ECG recording (Escoubet et al). 1986; 39:361-8

The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects (Lenders et al). 1986; 39:353-7

#### Acetaldehyde

Diphenhydramine and the calcium carbimide-ethanol reaction: A placebo-controlled clinical study (Stowell et al). 1986; 39:521-5

#### Acetaminophen

Comparison of oral nalbuphine, acetaminophen, and their combination in postoperative pain (Jain et al). 1986; 39:295-9

Ketorolac and acetaminophen for orthopedic postoperative pain (McQuay et al). 1986; 39:89-93

#### Acetylsalicylic acid

Evaluation of a potential drug interaction between sucralfate and aspirin (Lau et al). 1986; 39:151-5

Salicylate metabolism: Effects of age and sex in adults (Montgomery et al). 1986; 39:571-6

#### Acquired immune deficiency syndrome

Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome (Stahl-Bayliss et al). 1986; 39:271-5

#### Acutrim

Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modification (Weintraub et al). 1986; 39:501-9

#### Acyl glucuronide conjugate

Salicylate metabolism: Effects of age and sex in adults (Montgomery et al). 1986; 39:571-6

#### Adrenergic agonist

Concentration-dependent blood pressure effects of guanfacine (Frisk-Holmberg and Wibell). 1986; 39:169-72

Pharmacodynamics of midodrine, an antihypotensive agent (Zachariah et al). 1986; 39:586-91

#### Adrenergic function; see also Adrenergic agonist; Beta blocker; Beta receptor

Effect of diclofenac, a novel antidepressant, on peripheral adrenergic function (Gasić et al). 1986; 39:582-5

#### Age; see also Child; Elderly

The effect of age on ranitidine pharmacokinetics (Greene et al). 1986; 39:300-5

Salicylate metabolism: Effects of age and sex in adults (Montgomery et al). 1986; 39:571-6

Xylose disposition as a function of age (Johnson et al). 1986; 39:697-702

#### AIDS; see Acquired immune deficiency syndrome

#### Albumin

Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin (Urien et al). 1986; 39:683-9

#### Alcohol

Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics (Beach et al). 1986; 39:265-70

#### Alizapride

The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: A prospective, randomized, double-blind trial (Joss et al). 1986; 39:619-24

#### Alpha-1 acid glycoprotein

Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin (Urien et al). 1986; 39:683-9

#### Alprazolam

An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies (Grasela Jr et al). 1986; 39:605-12

#### American Society for Clinical Pharmacology and Therapeutics

Abstracts. 1986; 39:176-238

A letter to the members. 1986; 39:432

A message from the President. 1986; 39:106

New members of the Society. 1986; 39:600-2

#### Amiloride

Comparison of the effects of muzolimine and a fixed combination of diuretics in essential hypertension (Wicker and Clementy). 1986; 39:537-42

#### Aminoglycoside

Factors affecting aminoglycoside disposition: Effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics (Dickson et al). 1986; 39:325-8

#### Amitriptyline

Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers (Mellström et al). 1986; 39:369-71

Analgesic and antidepressant effects of low-dose amitriptyline in relation to its metabolism in patients with chronic pain (Edelbroek et al). 1986; 39:156-62

#### Amlodipine maleate

Amlodipine maleate (USAN List No. 268). 1986; 39:104

#### Analgesia

Comparison of oral nalbuphine, acetaminophen, and their combination in postoperative pain (Jain et al). 1986; 39:295-9

#### Analgesic; see also specific agent

Analgesic and antidepressant effects of low-dose amitriptyline in relation to its metabolism in patients with chronic pain (Edelbroek et al). 1986; 39:156-62

Ketorolac and acetaminophen for orthopedic postoperative pain (McQuay et al). 1986; 39:89-93

#### Angina

Comparative effects of metoprolol and celiprolol on cardiac hemodynamics and left ventricular volume at rest and during exercise-induced angina (Silke et al). 1986; 39:5-14

#### Angiotensin

Short-term augmented calcium intake has no effect on sodium homeostasis (Luft et al). 1986; 39:414-9

- Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects (Bussein et al). 1986; **39**:554-8
- Antiarrhythmic**; *see* specific agent
- Antidepressant**  
Analgesic and antidepressive effects of low-dose amitriptyline in relation to its metabolism in patients with chronic pain (Edelbroek et al). 1986; **39**:156-62  
Effect of diclofenac, a novel antidepressant, on peripheral adrenergic function (Gasic et al). 1986; **39**:582-5
- Antiemetic**  
The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: A prospective, randomized, double-blind trial (Joss et al). 1986; **39**:619-24
- Antifungal**  
Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion (Glynn et al). 1986; **39**:654-9
- Antihistamine**  
Diphenhydramine and the calcium carbimide-ethanol reaction: A placebo-controlled clinical study (Stowell et al). 1986; **39**:521-5
- Antihypertensive**; *see* Hypertension
- Antihypotensive**  
Pharmacodynamics of midodrine, an antihypotensive agent (Zachariah et al). 1986; **39**:586-91
- Antipyrene**  
Antipyrene kinetics in liver disease and liver transplantation (Mehta et al). 1986; **39**:372-7
- Antisickling agent**  
A single-dose pharmacokinetic study of the antisickling agent cettidil (Oringer et al). 1986; **39**:276-81
- Apazone**  
Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin (Urien et al). 1986; **39**:683-9
- Arthritis**  
Etodolac kinetics in the elderly (Scatina et al). 1986; **39**:550-3
- Arthroplasty**  
Dihydroergotamine and mobilization after major orthopedic surgery (Duus et al). 1986; **39**:342-4
- Aspirin**; *see* Acetylsalicylic acid
- Asthma**  
Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma (Greenberger et al). 1986; **39**:163-8  
Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma (Wilxon et al). 1986; **39**:29-34
- Atenolol**  
The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects (Lenders et al). 1986; **39**:353-7
- Atiprosin maleate**  
Atiprosin maleate (USAN List No. 271). 1986; **39**:433
- Automatic interaction detector method**  
Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance (Crom et al). 1986; **39**:592-7
- Avilamycin**  
Avilamycin (USAN List No. 270). 1986; **39**:359
- Award in Experimental Therapeutics**  
From "grass" roots to clinical utility (Lemberger). 1986; **39**:1-4 (Commentary)
- B**
- Behavior**  
Comparison of two benzodiazepines with differing accumulation: Behavioral changes during and after 3 weeks of dosing (Ghoneim et al). 1986; **39**:491-500  
Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modification (Weintraub et al). 1986; **39**:501-9
- Benzamide**  
The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: A prospective, randomized, double-blind trial (Joss et al). 1986; **39**:619-24
- Benzodiazepine**  
Comparison of two benzodiazepines with differing accumulation: Behavioral changes during and after 3 weeks of dosing (Ghoneim et al). 1986; **39**:491-500  
Quazepam and temazepam: Effects of short- and intermediate-term use and withdrawal (Kales et al). 1986; **39**:345-52
- Bepridil**  
Digoxin and bepridil: Pharmacokinetic and pharmacodynamic interactions (Belz et al). 1986; **39**:65-71
- Beta blocker**  
Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity (Möllerndorff et al). 1986; **39**:677-82  
Comparison of four beta-blockers as assessed by 24-hour ECG recording (Escoubet et al). 1986; **39**:361-8  
Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate (White et al). 1986; **39**:664-8  
Nifedipine tablet vs. hydralazine in patients with persisting hypertension who receive combined diuretic therapy and beta-blocker therapy (Myers et al). 1986; **39**:409-13  
Reduction of beta-adrenergic receptors by tertatolol: An additional mechanism for beta-adrenergic blockade (De Blasi et al). 1986; **39**:245-54  
Tolerance and beta-adrenergic blocking activity of fleistolol, a short-acting beta blocker (Turlapaty et al). 1986; **39**:543-9
- Beta receptor**; *see also* Beta blocker  
The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects (Lenders et al). 1986; **39**:353-7
- Betamethasone**  
Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration (Derendorf et al). 1986; **39**:313-7
- Bevantolol**  
Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma (Wilxon et al). 1986; **39**:29-34
- Beverages**  
Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines (Lelo et al). 1986; **39**:54-9
- Bilirubin**  
Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans (Anderson et al). 1986; **39**:510-20
- Bipyridine**  
Regional blood flow and neurohormonal responses to milrinone in congestive heart failure (Cody et al). 1986; **39**:128-35
- Blood pressure**; *see* Hypertension  
Changes in blood pressure and body fluid volumes during diuretic therapy in patients with essential hypertension who receive enalapril (van Schaik et al). 1986; **39**:60-4  
Concentration-dependent blood pressure effects of guanfacine (Frisk-Holmberg and Wibell). 1986; **39**:169-72

- Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate (White et al). 1986; 39:664-8
- Effects of meals on hemodynamics: Implications for antihypertensive drug studies (Fagan et al). 1986; 39:255-60
- Phenylpropanolamine and blood pressure (Morgan et al) (Letter); (Pentel et al) (Reply). 1986; 39:102-3
- BM 13.177**  
The pharmacokinetic and pharmacodynamic profiles of the thromboxane A<sub>2</sub> receptor blocker BM 13.177 (Patscheke et al). 1986; 39:145-50
- Books received**  
Books received. 1986; 39:360
- Britain; see United Kingdom**
- Bumetanide**  
Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure (Lau et al). 1986; 39:635-45
- Bupivacaine**  
The effect of nonesterified fatty acids and progesterone on bupivacaine protein binding (Coyle et al). 1986; 39:559-63
- Burns**  
Vancomycin elimination in patients with burn injury (Brater et al). 1986; 39:631-4

## C

- Cadexomer iodine**  
Cadexomer iodine (USAN List No. 268). 1986; 39:104
- Cadralazine**  
Effect of cadralazine on brachial artery hemodynamics and forearm venous tone in essential hypertension (Bouthier et al). 1986; 39:82-8
- Caffeine**  
Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrates of methylxanthines (Lelo et al). 1986; 39:54-9  
Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics (Beach et al). 1986; 39:265-70
- Calcium**  
Short-term augmented calcium intake has no effect on sodium homeostasis (Luft et al). 1986; 39:414-9
- Calcium carbimide**  
Diphenhydramine and the calcium carbimide-ethanol reaction: A placebo-controlled clinical study (Stowell et al). 1986; 39:521-5
- Calcium channel blocker**  
Hemodynamic and metabolic effects of the calcium channel blocking agent nitrendipine (Johnson et al). 1986; 39:389-94
- Cancer chemotherapy**  
The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: A prospective, randomized, double-blind trial (Joss et al). 1986; 39:619-24  
Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations (Bjornsson et al). 1986; 39:25-8
- Capsule**  
Variability of steady-state digoxin kinetics during administration of tablets or capsules (Johnson et al). 1986; 39:306-12
- Captopril**  
Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. 1986; 39:43-8
- Carbohydrate**  
Effects of meals on hemodynamics: Implications for antihypertensive drug studies (Fagan et al). 1986; 39:255-60

## Carbon 14-glyburide

- Pharmacokinetic disposition of <sup>14</sup>C-glyburide in patients with varying renal function (Pearson et al). 1986; 39:318-24
- Career development; see also Education**  
Clinical pharmacology teaching, training and career development (Nies and Breckenridge). 1986; 39:466-70 (Symposium)
- Carvedilol**  
Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity (Möllerndorff et al). 1986; 39:677-82
- Castor oil**  
Evaluation of an enkephalin analog in men with castor oil-induced diarrhea. 1986; 39:40-2
- Catecholamines**  
Treatment of childhood hyperactivity with d,sipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response (Donnelly et al). 1986; 39:72-81
- Celiprolol**  
Comparative effects of metoprolol and celiprolol on cardiac hemodynamics and left ventricular volume at rest and during exercise-induced angina (Silke et al). 1986; 39:5-14
- Central nervous system**  
Modulation of ethanol-induced central nervous system depression by ibuprofen (Minocha et al). 1986; 39:123-7
- Cetamolol**  
Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate (White et al). 1986; 39:664-8
- Cetiedil**  
A single-dose pharmacokinetic study of the antisickling agent cetiedil (Orringer et al). 1986; 39:276-81
- <sup>14</sup>C-glyburide**  
Pharmacokinetic disposition of <sup>14</sup>C-glyburide in patients with varying renal function (Pearson et al). 1986; 39:318-24
- Chemotherapy**  
The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: A prospective, randomized, double-blind trial (Joss et al). 1986; 39:619-24  
Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations (Bjornsson et al). 1986; 39:25-8
- Child; see also Age**  
Effect of clonidine on plasma cortisol concentrations (Ellis et al). 1986; 39:660-3  
Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response (Donnelly et al). 1986; 39:72-81  
Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance (Crom et al). 1986; 39:592-7
- Chlorthalidone**  
Changes in blood pressure and body fluid volumes during diuretic therapy in patients with essential hypertension who receive enalapril (van Schaik et al). 1986; 39:60-4
- Cholestyramine**  
Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide (Hunninghake et al). 1986; 39:329-34
- Cigarette smoking**  
Effects of nicotine chewing gum on cigarette smoking and subjective and physiologic effects (Nemeth-Coslett and Henningfield). 1986; 39:625-30
- Cilazapril**  
Cilazapril (USAN List No. 268). 1986; 39:104

**Cimaterol**

Cimaterol (USAN List No. 268). 1986; 39:104

**Cimetidine**

Ranitidine at very large doses does not inhibit theophylline elimination (Kelly et al). 1986; 39:577-81

**Circadian rhythm**

Factors affecting aminoglycoside disposition: Effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics (Dickson et al). 1986; 39:325-8

**Circulation**

Prostaglandins and the control of the circulation (Nies). 1986; 39:481-8 (Commentary)

**Cisplatin**

Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin (Vermorken et al). 1986; 39:136-44

**Clavulanate potassium**

Clavulanate potassium (USAN List No.273). 1986; 39:706

**Clinical pharmacologist**

Clinical pharmacologists for the future in the United Kingdom (McDevitt). 1986; 39:459-61 (Symposium)

Clinical pharmacologists for the future in the United States (Oates). 1986; 39:462-5 (Symposium)

A description of clinical pharmacology and the clinical pharmacologist (Crout). 1986; 39:439 (Symposium)

**Clinical pharmacology**

Academic pursuits in clinical pharmacology: Research emphasis (Mitchell and Grahame-Smith). 1986; 39:471-3 (Symposium)

Clinical pharmacology teaching, training and career development (Nies and Breckenridge). 1986; 39:466-70 (Symposium)

Current status of clinical pharmacology in the United Kingdom (Turner). 1986; 39:448-50 (Symposium)

Current status of clinical pharmacology training in the United States (Peck and Crout). 1986; 39:451-8 (Symposium)

A description of clinical pharmacology and the clinical pharmacologist (Crout). 1986; 39:439 (Symposium)

Present status and future directions of clinical pharmacology; Introduction (Melmon and Turner). 1986; 39:435-6 (Symposium)

The public need for clinical pharmacology in the United Kingdom (Dollery). 1986; 39:440-2 (Symposium)

The public need for clinical pharmacology in the United States (Melmon). 1986; 39:443-7 (Symposium)

**Clonidine**

Effect of clonidine on plasma cortisol concentrations (Ellis et al). 1986; 39:660-3

**Coffee**

Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrates of methylxanthines (Lelo et al). 1986; 39:54-9

**Combination therapy**

Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. 1986; 39:43-8

**Commentary**

Commentary. 1986; 39:1-4, 239-44, 481-90

**Computer study**

An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies (Grasela Jr et al). 1986; 39:605-12

**Congestive heart failure**

Regional blood flow and neurohormonal responses to milrinone in congestive heart failure (Cody et al). 1986; 39:128-35

**Contraceptives**

Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives (Legler and Benet). 1986; 39:425-9

Oral contraceptives and other risk factors for gallbladder disease (Strom et al). 1986; 39:335-41

**Correspondence**

Letters. 1986; 39:102-3, 598-9

**Corticosteroids; see Steroids****Cortisol**

Effect of clonidine on plasma cortisol concentrations (Ellis et al). 1986; 39:660-3

Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion (Glynn et al). 1986; 39:654-9

**Crebentine**

Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance (Crom et al). 1986; 39:592-7

Vancomycin elimination in patients with burn injury (Brater et al). 1986; 39:631-4

**Cyanamide**

Diphenhydramine and the calcium carbimide-ethanol reaction: A placebo-controlled clinical study (Stowell et al). 1986; 39:521-5

**D****Darodipine**

Darodipine (USAN List No. 270). 1986; 39:358

**Debrisoquin**

Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers (Mellström et al). 1986; 39:369-71

Co-inheritance of the polymorphic metabolism of encainide and debrisoquin (Woosley et al). 1986; 39:282-7

**Delapril hydrochloride**

Delapril hydrochloride (USAN List No. 269). 1986; 39:173

**Depression**

Analgesic and antidepressive effects of low-dose amitriptyline in relation to its metabolism in patients with chronic pain (Edelbroek et al). 1986; 39:156-62

Effect of diclofenine, a novel antidepressant, on peripheral adrenergic function (Gasić et al). 1986; 39:582-5

Modulation of ethanol-induced central nervous system depression by ibuprofen (Minocha et al). 1986; 39:123-7

**Desipramine**

Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response (Donnelly et al). 1986; 39:72-81

**Desmethylinipramine**

Effect of diclofenine, a novel antidepressant, on peripheral adrenergic function (Gasić et al). 1986; 39:582-5

**Diarrhea**

Evaluation of an enkephalin analog in men with castor oil-induced diarrhea. 1986; 39:40-2

**Diazepam**

Comparison of two benzodiazepines with differing accumulation: Behavioral changes during and after 3 weeks of dosing (Ghoneim et al). 1986; 39:491-500

**Diclofenine**

Effect of diclofenine, a novel antidepressant, on peripheral adrenergic function (Gasić et al). 1986; 39:582-5

**Diet; see also Food**

Factors affecting aminoglycoside disposition: Effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics (Dickson et al). 1986; 39:325-8

Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modification (Weintraub et al). 1986; 39:501-9

**Digitoxin**

Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions (Kuhlmann et al). 1986; 39:288-94

# Digoxin

Digoxin and bepridil: Pharmacokinetic and pharmacodynamic interactions (Belz et al). 1986; 39:65-71

Dose-dependence of the nifedipine-digoxin interaction? (Kirch et al). 1986; 39:35-9

Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations (Bjornsson et al). 1986; 39:25-8

Interpretation of serum digoxin values in renal failure (Gault et al). 1986; 39:530-6

Variability of steady-state digoxin kinetics during administration of tablets or capsules (Johnson et al). 1986; 39:306-12

# Dihydroergotamine

Dihydroergotamine and mobilization after major orthopedic surgery (Duus et al). 1986; 39:342-4

# Diphenhydramine

Diphenhydramine and the calcium carbimide-ethanol reaction: A placebo-controlled clinical study (Stowell et al). 1986; 39:521-5

# Disulfiram

Diphenhydramine and the calcium carbimide-ethanol reaction: A placebo-controlled clinical study (Stowell et al). 1986; 39:521-5

Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics (Beach et al). 1986; 39:265-70

# Diuretic

The antihypertensive action of hydrochlorothiazide and renal prostacyclin (Wilson). 1986; 39:94-101

The cardiovascular risks of thiazide diuretics (Freis). 1986; 39:239-44 (Commentary)

Changes in blood pressure and body fluid volumes during diuretic therapy in patients with essential hypertension who receive enalapril (van Schaik et al). 1986; 39:60-4

Comparison of the effects of muzolimine and a fixed combination of diuretics in essential hypertension (Wicker and Clementy). 1986; 39:537-42

Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide (Hunninghake et al). 1986; 39:329-34

Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure (Lau et al). 1986; 39:635-45

Nifedipine tablet vs. hydralazine in patients with persisting hypertension who receive combined diuretic therapy and beta-blocker therapy (Myers et al). 1986; 39:409-13

# Dopamine

Effect of diclofenac, a novel antidepressant, on peripheral adrenergic function (Gasic et al). 1986; 39:582-5

Metoclopramide decreases renal plasma flow (Israel et al). 1986; 39:261-4

# Dose-dependence

Dose-dependence of the nifedipine-digoxin interaction? (Kirch et al). 1986; 39:35-9

# Dose-dumping

No "dose-dumping" with once-a-day Uniphyll (Goldenheim) (Letter); (Karim) (Reply). 1986; 39:598-9

# Duoperone fumarate

Duoperone fumarate (USAN List No. 271). 1986; 39:434

## E

# ECG; see Electrocardiogram

# Economics

Workshop report: Fiscal support (Lemberger and Rawlins). 1986; 39:477-80 (Symposium)

# Education

Clinical pharmacology teaching, training and career development (Nies and Breckenridge). 1986; 39:466-70 (Symposium)

Current status of clinical pharmacology training in the United States (Peck and Croul). 1986; 39:451-8 (Symposium)

# Eflornithine hydrochloride

Eflornithine hydrochloride (USAN List No. 269). 1986; 39:173

# Elderly; see also Age

Etodolac kinetics in the elderly (Scatina et al). 1986; 39:550-3

Xylose disposition as a function of age (Johnson et al). 1986; 39:697-702

# Electrocardiogram

Comparison of four beta-blockers as assessed by 24-hour ECG recording (Escoubet et al). 1986; 39:361-8

# Emesis

The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: A prospective, randomized, double-blind trial (Joss et al). 1986; 39:619-24

# Enalapril

Changes in blood pressure and body fluid volumes during diuretic therapy in patients with essential hypertension who receive enalapril (van Schaik et al). 1986; 39:60-4

# Enantiomer

Pharmacokinetics of (±), (+), and (−)-gossypol in humans and dogs (Wu et al). 1986; 39:613-18

# Encainide

Co-inheritance of the polymorphic metabolism of encainide and debrisoquin (Woosley et al). 1986; 39:282-7

# Enkephalin analog

Evaluation of an enkephalin analog in men with castor oil-induced diarrhea. 1986; 39:40-2

# Enoximone

Enoximone (USAN List No. 270). 1986; 39:358

# Enprofylline

Cardiovascular effects of enprofylline and theophylline (Esquivel et al). 1986; 39:395-402

# Epinephrine

Indomethacin attenuates the hypotensive action of hydralazine (Cinquemani and Liang). 1986; 39:564-70

# Ethanol

Diphenhydramine and the calcium carbimide-ethanol reaction: A placebo-controlled clinical study (Stowell et al). 1986; 39:521-5

# Etodolac

Etodolac kinetics in the elderly (Scatina et al). 1986; 39:550-3

# Exercise

Comparative effects of metoprolol and celiprolol on cardiac hemodynamics and left ventricular volume at rest and during exercise-induced angina (Silke et al). 1986; 39:5-14

Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate (White et al). 1986; 39:664-8

Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modification (Weintraub et al). 1986; 39:501-9

# Experimental Therapeutics award

From "grass" roots to clinical utility (Lemberger). 1986; 39:1-4 (Commentary)

# Extended least-squares analysis

An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies (Grasela Jr et al). 1986; 39:605-12

## F

# Fatty acids

The effect of nonesterified fatty acids and progesterone on bupivacaine protein binding (Coyle et al). 1986; 39:559-63

Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin (Urien et al). 1986; 39:683-9

#### Finances

Workshop report: Fiscal support (Lemberger and Rawlins). 1986; 39:477-80

#### Finger

The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects (Lenders et al). 1986; 39:353-7

#### Fiscal support

Workshop report: Fiscal support (Lemberger and Rawlins). 1986; 39:477-80 (Symposium)

#### Fleotolol

Tolerance and beta-adrenergic blocking activity of fleotolol, a short-acting beta blocker (Turlapaty et al). 1986; 39:543-9

#### Food; see also Diet

Effects of meals on hemodynamics: Implications for antihypertensive drug studies (Fagan et al). 1986; 39:255-60

#### Fosinopril sodium

Fosinopril sodium (USAN List No. 269). 1986; 39:173

#### Funding

Workshop report: Fiscal support (Lemberger and Rawlins). 1986; 39:477-80

#### Fungus

Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion (Glynn et al). 1986; 39:654-9

#### Future directions

Clinical pharmacologists for the future in the United Kingdom (McDevitt). 1986; 39:459-61 (Symposium)

Clinical pharmacologists for the future in the United States (Oates). 1986; 39:462-5 (Symposium)

Present status and future directions of clinical pharmacology: Introduction (Melmon and Turner). 1986; 39:435-6 (Symposium)

### G

#### Gallbladder

Oral contraceptives and other risk factors for gallbladder disease (Strom et al). 1986; 39:335-41

#### Gender

Salicylate metabolism: Effects of age and sex in adults (Montgomery et al). 1986; 39:571-6

Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance (Crom et al). 1986; 39:592-7

#### Genetics

Co-inheritance of the polymorphic metabolism of encainide and debrisoquin (Woosley et al). 1986; 39:282-7

#### Gentamicin

Factors affecting aminoglycoside disposition: Effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics (Dickson et al). 1986; 39:325-8

#### Gloximonam

Gloximonam (USAN List No. 272). 1986; 39:603

#### Glucocorticoids

Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion (Glynn et al). 1986; 39:654-9

Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration (Derendorf et al). 1986; 39:313-7

#### Glycoprotein

Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin (Urien et al). 1986; 39:683-9

#### Gossypol

Pharmacokinetics of ( $\pm$ )-, (+)-, and (-)-gossypol in humans and dogs (Wu et al). 1986; 39:613-18

#### Growth hormone

Effect of clonidine on plasma cortisol concentrations (Ellis et al). 1986; 39:660-3

#### Guanfacine

Concentration-dependent blood pressure effects of guanfacine (Frisk-Holmberg and Wibell). 1986; 39:169-72

#### Gum

Effects of nicotine chewing gum on cigarette smoking and subjective and physiologic effects (Nemeth-Coslett and Henningfield). 1986; 39:625-30

### H

#### Health care

Health care and patient services (Petrie and Reidenberg). 1986; 39:474-6 (Symposium)

#### Heart

Cardiovascular effects of enprofylline and theophylline (Esquivel et al). 1986; 39:395-402

The cardiovascular risks of thiazide diuretics (Freis). 1986; 39:239-44 (Commentary)

Comparative effects of metoprolol and celiprolol on cardiac hemodynamics and left ventricular volume at rest and during exercise-induced angina (Silke et al). 1986; 39:5-14

Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate (White et al). 1986; 39:664-8

Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma (Wilxon et al). 1986; 39:29-34

Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response (Donnelly et al). 1986; 39:72-81

#### Heart failure

Regional blood flow and neurohormonal responses to milrinone in congestive heart failure (Cody et al). 1986; 39:128-35

#### Hemodialysis

Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis (Williams et al). 1986; 39:420-4

#### Heredity

Co-inheritance of the polymorphic metabolism of encainide and debrisoquin (Woosley et al). 1986; 39:282-7

#### Heroin substitute

The pharmacokinetics of pentazocine and tripeleminamine (Yeh et al). 1986; 39:669-76

#### Hip surgery

Dihydroergotamine and mobilization after major orthopedic surgery (Duus et al). 1986; 39:342-4

#### Histamine receptor

Ranitidine at very large doses does not inhibit theophylline elimination (Kelly et al). 1986; 39:577-81

#### Hydralazine

Indomethacin attenuates the hypotensive action of hydralazine (Cinquegrani and Liang). 1986; 39:564-70

Nifedipine tablet vs. hydralazine in patients with persisting hypertension who receive combined diuretic therapy and beta-blocker therapy (Myers et al). 1986; 39:409-13

#### Hydrochlorothiazide

The antihypertensive action of hydrochlorothiazide and renal prostacyclin (Wilson). 1986; 39:94-101

Comparison of the effects of muzolimine and a fixed combination of diuretics in essential hypertension (Wicker and Clementy). 1986; 39:537-42

- Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide (Hunninghake et al). 1986; 39:329-34
- Hyperactivity**  
Treatment of childhood hyperactivity with desipramine: Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response (Donnelly et al). 1986; 39:72-81
- Hyperbilirubinemia**  
Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans (Anderson et al). 1986; 39:510-20
- Hypertension; see also Blood pressure**  
Acute effects of increasing doses of urapidil in patients with hypertension (Culbertson et al). 1986; 39:690-6  
The antihypertensive action of hydrochlorothiazide and renal prostacyclin (Wilson). 1986; 39:94-101  
Changes in blood pressure and body fluid volumes during diuretic therapy in patients with essential hypertension who receive enalapril (van Schaik et al). 1986; 39:60-4  
Chronic effects of pindolol on the arterioles, large arteries, and veins of the forearm in mild to moderate essential hypertension (Maarek et al). 1986; 39:403-8  
Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity (Möllerndorff et al). 1986; 39:677-82  
Comparison of the effects of mizolimine and a fixed combination of diuretics in essential hypertension (Wicker and Clementy). 1986; 39:537-42  
Effect of cadralazine on brachial artery hemodynamics and forearm venous tone in essential hypertension (Bouthier et al). 1986; 39:82-8  
Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rate (White et al). 1986; 39:664-8  
Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. 1986; 39:43-8  
Effects of meals on hemodynamics: Implications for antihypertensive drug studies (Fagan et al). 1986; 39:255-60  
Hemodynamic and metabolic effects of the calcium channel blocking agent nitrendipine (Johnson et al). 1986; 39:389-94  
Indomethacin attenuates the hypotensive action of hydralazine (Cinquegrani and Liang). 1986; 39:564-70  
Nifedipine tablet vs. hydralazine in patients with persisting hypertension who receive combined diuretic therapy and beta-blocker therapy (Myers et al). 1986; 39:409-13
- Hypnotics**  
Quazepam and temazepam: Effects of short- and intermediate-term use and withdrawal (Kales et al). 1986; 39:345-52
- Hypoglycemia**  
Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome (Stahl-Bayliss et al). 1986; 39:271-5
- Hypotension**  
Indomethacin attenuates the hypotensive action of hydralazine (Cinquegrani and Liang). 1986; 39:564-70  
Pharmacodynamics of midodrine, an antihypotensive agent (Zachariah et al). 1986; 39:586-91
- I**
- Ibuprofen**  
Modulation of ethanol-induced central nervous system depression by ibuprofen (Minocha et al). 1986; 39:123-7
- Immune deficiency**  
Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome (Stahl-Bayliss et al). 1986; 39:271-5
- Indomethacin**  
Indomethacin attenuates the hypotensive action of hydralazine (Cinquegrani and Liang). 1986; 39:564-70
- Inheritance**  
Co-inheritance of the polymorphic metabolism of encainide and debrisoquin (Woosley et al). 1986; 39:282-7
- Injury**  
Vancomycin elimination in patients with burn injury (Brater et al). 1986; 39:631-4
- Interaction**  
Comparison of oral nalbuphine, acetaminophen, and their combination in postoperative pain (Jain et al). 1986; 39:295-9  
Digoxin and bepridil: Pharmacokinetic and pharmacodynamic interactions (Belz et al). 1986; 39:65-71  
Dose-dependence of the nifedipine-digoxin interaction? (Kirch et al). 1986; 39:35-9  
Evaluation of a potential drug interaction between sucralate and aspirin (Lau et al). 1986; 39:151-5  
Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co-regulated substrate, mephobarbital (Jacqz et al). 1986; 39:646-53  
Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance (Crom et al). 1986; 39:592-7  
The warfarin-sulfinpyrazone interaction: Stereochemical considerations (Toon et al). 1986; 39:15-24
- Intra-articular glucocorticoid**  
Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration (Derendorf et al). 1986; 39:313-7
- Intravenous administration**  
Metabolism of nomifensine after oral and intravenous administration (Lindberg and Syvälahti). 1986; 39:378-83  
Nalmefene: Intravenous safety and kinetics of a new opioid antagonist (Dixon et al). 1986; 39:49-53  
Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin (Vermorken et al). 1986; 39:136-44
- Iotrolan**  
Iotrolan (USAN List No. 268). 1986; 39:104
- Isomazole hydrochloride**  
Isomazole hydrochloride (USAN List No. 271). 1986; 39:434
- Isoproterenol**  
Tolerance and beta-adrenergic blocking activity of fleistolol, a short-acting beta blocker (Turlapaty et al). 1986; 39:543-9
- Itazogrel**  
Itazogrel (USAN List No. 273). 1986; 39:705
- K**
- Ketoconazole**  
Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion (Glynn et al). 1986; 39:654-9
- Ketorolac**  
Ketorolac and acetaminophen for orthopedic postoperative pain (McQuay et al). 1986; 39:89-93
- Kidney**  
The antihypertensive action of hydrochlorothiazide and renal prostacyclin (Wilson). 1986; 39:94-101  
Interpretation of serum digoxin values in renal failure (Gault et al). 1986; 39:530-6  
Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure (Lau et al). 1986; 39:635-45  
Metoclopramide decreases renal plasma flow (Israel et al). 1986; 39:261-4  
Pharmacokinetic disposition of <sup>14</sup>C-glyburide in patients with varying renal function (Pearson et al). 1986; 39:318-24

Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis (Williams et al). 1986; 39:420-4

Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance (Crom et al). 1986; 39:592-7

## L

**Least-squares analysis**

An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies (Grasela Jr et al). 1986; 39:605-12

**Left ventricle**

Comparative effects of metoprolol and celiprolol on cardiac hemodynamics and left ventricular volume at rest and during exercise-induced angina (Silke et al). 1986; 39:5-14

**Letters**

Letters. 1986; 39:102-3, 598-9

**Leukemia**

Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance (Crom et al). 1986; 39:592-7

**Linogiride**

Linogiride (USAN List No. 271). 1986; 39:434

**List of reviewers**

List of reviewers. 1986; 39:430-1

**Liver**

Antipyrine kinetics in liver disease and liver transplantation (Mehta et al). 1986; 39:372-7

Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance (Crom et al). 1986; 39:592-7

**Lofexidine hydrochloride**

Lofexidine hydrochloride (USAN List No. 271). 1986; 39:433

**Lonapalene**

Lonapalene (USAN List No. 273). 1986; 39:705

**Loratadine**

Loratadine (USAN List No. 273). 1986; 39:705

**Lorazepam**

Sedative effects and impaired learning and recall after single oral doses of lorazepam (Shader et al). 1986; 39:526-9

**Lortalamine**

Lortalamine (USAN List No. 272). 1986; 39:604

**Lymphocytic leukemia**

Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance (Crom et al). 1986; 39:592-7

## M

**Meals; see also Diet**

Effects of meals on hemodynamics: Implications for antihypertensive drug studies (Fagan et al). 1986; 39:255-60

**Memory**

Sedative effects and impaired learning and recall after single oral doses of lorazepam (Shader et al). 1986; 39:526-9

**Menogaril**

Menogaril (USAN List No. 269). 1986; 39:173

**Mephenytoin**

Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co-regulated substrate, mephobarbital (Jacqz et al). 1986; 39:646-53

**Mephobarbital**

Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co-regulated substrate, mephobarbital (Jacqz et al). 1986; 39:646-53

**Mesalamine**

Mesalamine (USAN List No. 272). 1986; 39:603

**Metabolism**

Co-inheritance of the polymorphic metabolism of encainide and debrisoquin (Woosley et al). 1986; 39:282-7

No "dose-dumping" with once-a-day Uniphyl (Goldenheim) (Letter); (Karim) (Reply). 1986; 39:598-9

Pharmacodynamics of midodrine, an antihypotensive agent (Zachariah et al). 1986; 39:586-91

Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co-regulated substrate, mephobarbital (Jacqz et al). 1986; 39:646-53

Ranitidine at very large doses does not inhibit theophylline elimination (Kelly et al). 1986; 39:577-81

Salicylate metabolism: Effects of age and sex in adults (Montgomery et al). 1986; 39:571-6

**Methotrexate**

Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance (Crom et al). 1986; 39:592-7

**Methylprednisolone**

Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion (Glynn et al). 1986; 39:654-9

**Methylxanthines**

Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines (Lelo et al). 1986; 39:54-9

**Metoclopramide**

The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: A prospective, randomized, double-blind trial (Joss et al). 1986; 39:619-24

Metoclopramide decreases renal plasma flow (Israel et al). 1986; 39:261-4

**Metoprolol**

Comparative effects of metoprolol and celiprolol on cardiac hemodynamics and left ventricular volume at rest and during exercise-induced angina (Silke et al). 1986; 39:5-14

Comparison of four beta-blockers as assessed by 24-hour ECG recording (Escoubet et al). 1986; 39:361-8

Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma (Wilxon et al). 1986; 39:29-34

**Midodrine**

Pharmacodynamics of midodrine, an antihypotensive agent (Zachariah et al). 1986; 39:586-91

**Milacemide hydrochloride**

Milacemide hydrochloride (USAN List No. 272). 1986; 39:603

**Milrinone**

Regional blood flow and neurohormonal responses to milrinone in congestive heart failure (Cody et al). 1986; 39:128-35

**Mobilization**

Dihydroergotamine and mobilization after major orthopedic surgery (Duus et al). 1986; 39:342-4

**Muzolimine**

Comparison of the effects of muzolimine and a fixed combination of diuretics in essential hypertension (Wicker and Clementy). 1986; 39:537-42

## N

**Nadolol**

Comparison of four beta-blockers as assessed by 24-hour ECG recording (Escoubet et al). 1986; 39:361-8

**Nalbuphine**

Comparison of oral nalbuphine, acetaminophen, and their combination in postoperative pain (Jain et al). 1986; 39:295-9

**Nalmefene**

Nalmefene: Intravenous safety and kinetics of a new opioid antagonist (Dixon et al). 1986; 39:49-53

# **Neflumozide hydrochloride**

Neflumozide hydrochloride (USAN List No. 270). 1986; 39:359

# **Netobimin**

Netobimin (USAN List No. 271). 1986; 39:433

# **Neurohormonal response**

Regional blood flow and neurohormonal responses to milrinone in congestive heart failure (Cody et al). 1986; 39:128-35

# **Nicotine gum**

Effects of nicotine chewing gum on cigarette smoking and subjective and physiologic effects (Nemeth-Coslett and Henningfield). 1986; 39:625-30

# **Nifalutide**

Evaluation of an enkephalin analog in men with castor oil-induced diarrhea. 1986; 39:40-2

# **Nifedipine**

Dose-dependence of the nifedipine-digoxin interaction? (Kirch et al). 1986; 39:35-9

Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. 1986; 39:43-8

Nifedipine tablet vs. hydralazine in patients with persisting hypertension who receive combined diuretic therapy and beta-blocker therapy (Myers et al). 1986; 39:409-13

# **Nitrendipine**

Hemodynamic and metabolic effects of the calcium channel blocking agent nitrendipine (Johnson et al). 1986; 39:389-94

# **Nomifensine**

Disposition of nomifensine after acute and prolonged dosing (Lindberg et al). 1986; 39:384-8

Metabolism of nomifensine after oral and intravenous administration (Lindberg and Syvälahti). 1986; 39:378-83

# **Nonesterified fatty acids**

The effect of nonesterified fatty acids and progesterone on bu-pivacaine protein binding (Coyle et al). 1986; 39:559-63

Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin (Urien et al). 1986; 39:683-9

# **NONMEM**

An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies (Grasela Jr et al). 1986; 39:605-12

# **Norepinephrine**

Effect of diclofenac, a novel antidepressant, on peripheral ad-renergic function (Gasić et al). 1986; 39:582-5

Indomethacin attenuates the hypotensive action of hydralazine (Cinquemani and Liang). 1986; 39:564-70

# **Nortriptyline**

Amitriptyline metabolism: Association with debrisoquin hydrox-ylation in nonsmokers (Mellström et al). 1986; 39:369-71

## **O**

# **Omeprazole**

Omeprazole (USAN List No. 268). 1986; 39:104

# **Opioid antagonist**

Nalmefene: Intravenous safety and kinetics of a new opioid antagonist (Dixon et al). 1986; 39:49-53

# **Oral administration**

Comparison of oral nalbuphine, acetaminophen, and their combination in postoperative pain (Jain et al). 1986; 39:295-9

The effect of age or ranitidine pharmacokinetics (Greene et al). 1986; 39:300-5

Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives (Legler and Benet). 1986; 39:425-9

Metabolism of nomifensine after oral and intravenous administration (Lindberg and Syvälahti). 1986; 39:378-83

Oral contraceptives and other risk factors for gallbladder disease (Strom et al). 1986; 39:335-41

Pharmacodynamics of midodrine, an antihypotensive agent (Zachariah et al). 1986; 39:586-91

Salicylate metabolism: Effects of age and sex in adults (Montgomery et al). 1986; 39:571-6

Sedative effects and impaired learning and recall after single oral doses of lorazepam (Shader et al). 1986; 39:526-9

Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects (Bussein et al). 1986; 39:554-8

# **Orthopedics**

Dihydroergotamine and mobilization after major orthopedic surgery (Duus et al). 1986; 39:342-4

Ketorolac and acetaminophen for orthopedic postoperative pain (McQuay et al). 1986; 39:89-93

# **Osmotic release oral system**

Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modification (Weintraub et al). 1986; 39:501-9

# **Osteoarthritis**

Etodolac kinetics in the elderly (Scatina et al). 1986; 39:550-3

# **Oxazepam**

Comparison of two benzodiazepines with differing accumulation: Behavioral changes during and after 3 weeks of dosing (Ghoneim et al). 1986; 39:491-500

## **P**

# **Pain**

Analgesic and antidepressive effects of low-dose amitriptyline in relation to its metabolism in patients with chronic pain (Edelbroek et al). 1986; 39:156-62

Comparison of oral nalbuphine, acetaminophen, and their combination in postoperative pain (Jain et al). 1986; 39:295-9

Ketorolac and acetaminophen for orthopedic postoperative pain (McQuay et al). 1986; 39:89-93

# **Paraxanthine**

Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrates of methylxanthines (Lelo et al). 1986; 39:54-9

# **Patient services**

Health care and patient services (Petrie and Reidenberg). 1986; 39:474-6 (Symposium)

# **Pentamidine**

Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome (Stahl-Bayliss et al). 1986; 39:271-5

# **Pentazocine**

The pharmacokinetics of pentazocine and tripeleminamine (Yeh et al). 1986; 39:669-76

# **Perindopril**

Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects (Bussein et al). 1986; 39:554-8

# **Pharmacologist; see Clinical pharmacologist**

# **Pharmacology; see Clinical pharmacology**

# **Phenolic glucuronide conjugate**

Salicylate metabolism: Effects of age and sex in adults (Montgomery et al). 1986; 39:571-6

# **Phenylephrine**

Effect of diclofenac, a novel antidepressant, on peripheral ad-renergic function (Gasić et al). 1986; 39:582-5

# **Phenylpropanolamine**

Phenylpropanolamine and blood pressure (Morgan et al) (Letter); (Pentel et al) (Reply). 1986; 39:102-3

Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modification (Weintraub et al). 1986; 39:501-9

**Pindolol**

Chronic effects of pindolol on the arterioles, large arteries, and veins of the forearm in mild to moderate essential hypertension (Maarek et al). 1986; 39:403-8

The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects (Lenders et al). 1986; 39:353-7

**Piritrexim isethionate**

Piritrexim isethionate (USAN List No. 273). 1986; 39:706

**Platinum**

Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin (Vermorken et al). 1986; 39:136-44

**Pneumonia**

Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome (Stahl-Bayliss et al). 1986; 39:271-5

**Postgraduate education**

Clinical pharmacology teaching, training and career development (Nies and Breckenridge). 1986; 39:466-70 (Symposium)

**Postoperative pain**

Comparison of oral nalbuphine, acetaminophen, and their combination in postoperative pain (Jain et al). 1986; 39:295-9

Ketorolac and acetaminophen for orthopedic postoperative pain (McQuay et al). 1986; 39:89-93

**Prednisolone**

Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma (Greenberger et al). 1986; 39:163-8

Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives (Legler and Benet). 1986; 39:425-9

**Prednisone**

Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma (Greenberger et al). 1986; 39:163-8

**Pregnancy**

The effect of nonesterified fatty acids and progesterone on bupivacaine protein binding (Coyle et al). 1986; 39:559-63

**Progesterone**

The effect of nonesterified fatty acids and progesterone on bupivacaine protein binding (Coyle et al). 1986; 39:559-63

**Propranolol**

Comparison of four beta-blockers as assessed by 24-hour ECG recording (Escoubet et al). 1986; 39:361-8

Hemodynamic and metabolic effects of the calcium channel blocking agent nitrendipine (Johnson et al). 1986; 39:389-94

The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects (Lenders et al). 1986; 39:353-7

**Prostacyclin**

The antihypertensive action of hydrochlorothiazide and renal prostacyclin (Wilson). 1986; 39:94-101

**Prostaglandin**

The antihypertensive action of hydrochlorothiazide and renal prostacyclin (Wilson). 1986; 39:94-101

Indomethacin attenuates the hypotensive action of hydralazine (Cinquemani and Liang). 1986; 39:564-70

Prostaglandins and the control of the circulation (Nies). 1986; 39:481-8 (Commentary)

**Prostaglandin synthetase inhibitor**

Modulation of ethanol-induced central nervous system depression by ibuprofen (Minocha et al). 1986; 39:123-7

**Protein**

The effect of nonesterified fatty acids and progesterone on bupivacaine protein binding (Coyle et al). 1986; 39:559-63

Factors affecting aminoglycoside disposition: Effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics (Dickson et al). 1986; 39:325-8

**Protoporphyrin**

Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans (Anderson et al). 1986; 39:510-20

**Q****Quazepam**

Quazepam and temazepam: Effects of short- and intermediate-term use and withdrawal (Kales et al). 1986; 39:345-52

**Quazolast**

Quazolast (USAN List No. 273). 1986; 39:706

**Quinidine**

Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions (Kuhlmann et al). 1986; 39:288-94

**R****Ramipril**

Ramipril (USAN List No. 272). 1986; 39:604

**Ranitidine**

The effect of age on ranitidine pharmacokinetics (Greene et al). 1986; 39:300-5

Ranitidine at very large doses does not inhibit theophylline elimination (Kelly et al). 1986; 39:577-81

**Recall**

Sedative effects and impaired learning and recall after single oral doses of lorazepam (Shader et al). 1986; 39:526-9

**Receptor; see also Beta blocker**

Concentration-dependent blood pressure effects of guanfacine (Frisk-Holmberg and Wibell). 1986; 39:169-72

The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects (Lenders et al). 1986; 39:353-7

The pharmacokinetic and pharmacodynamic profiles of the thromboxane A<sub>2</sub> receptor blocker BM 13.177 (Patscheke et al). 1986; 39:145-50

Ranitidine at very large doses does not inhibit theophylline elimination (Kelly et al). 1986; 39:577-81

Reduction of beta-adrenergic receptors by tertatolol: An additional mechanism for beta-adrenergic blockade (De Blasi et al). 1986; 39:245-54

**Regional blood flow**

Regional blood flow and neurohormonal responses to milrinone in congestive heart failure (Cody et al). 1986; 39:128-35

**Renal failure; see also Kidney**

Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure (Lau et al). 1986; 39:635-45

Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis (Williams et al). 1986; 39:420-4

**Renin**

Prostaglandins and the control of the circulation (Nies). 1986; 39:481-8 (Commentary)

Short-term augmented calcium intake has no effect on sodium homeostasis (Luft et al). 1986; 39:414-9

**Research**

Academic pursuits in clinical pharmacology: Research emphasis (Mitchell and Grahame-Smith). 1986; 39:471-3 (Symposium)

**Respiration**

Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma (Wilson et al). 1986; 39:29-34

## Reviewers

List of reviewers. 1986; 39:430-1

## Rimazole hydrochloride

Rimazole hydrochloride (USAN List No. 270). 1986; 39:358

## S

### Salicylate

Salicylate metabolism: Effects of age and sex in adults (Montgomery et al). 1986; 39:571-6

### Salsalate

Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis (Williams et al). 1986; 39:420-4

### Sample size

Sample size calculations for clinical pharmacology studies (Stolley and Strom). 1986; 39:489-90 (Commentary)

### Sedatives; see also specific agent

Sedative effects and impaired learning and recall after single oral doses of lorazepam (Shader et al). 1986; 39:526-9

### Serotonin

Effect of diclofenac, a novel antidepressant, on peripheral adrenergic function (Gasic et al). 1986; 39:582-5

### Sex; see Gender

### Skin temperature

The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects (Lenders et al). 1986; 39:353-7

### Smoking

Effects of nicotine chewing gum on cigarette smoking and subjective and physiologic effects (Nemeth-Coslett and Henningfield). 1986; 39:625-30

### Sodium

Short-term augmented calcium intake has no effect on sodium homeostasis (Luft et al). 1986; 39:414-9

### Statistics

An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies (Grasela Jr et al). 1986; 39:605-12

### Steroids

Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma (Greenberger et al). 1986; 39:163-8

Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion (Glynn et al). 1986; 39:654-9

Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration (Derendorf et al). 1986; 39:313-7

### Sucralfate

Evaluation of a potential drug interaction between sucralfate and aspirin (Lau et al). 1986; 39:151-5

### Sulfinpyrazone

The warfarin-sulfinpyrazone interaction: Stereochemical considerations (Toon et al). 1986; 39:15-24

### Sympathomimetic

The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects (Lenders et al). 1986; 39:353-7

### Symposium

Symposium: The Anglo-American workshop on clinical pharmacology. 1986; 39:435-80

### Syndrome

Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome (Stahl-Bayliss et al). 1986; 39:271-5

## Tablets

## T

Variability of steady-state digoxin kinetics during administration of tablets or capsules (Johnson et al). 1986; 39:306-12

### Tea

Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrates of methylxanthines (Lelo et al). 1986; 39:54-9

### Teaching; see Education

### Teicoplanin

Teicoplanin (USAN List No. 268). 1986; 39:104

### Temazepam

Quazepam and temazepam: Effects of short- and intermediate-term use and withdrawal (Kales et al). 1986; 39:345-52

### Temperature

The influence of intrinsic sympathomimetic activity and beta-1 receptor selectivity on the recovery of finger skin temperature after finger cooling in normotensive subjects (Lenders et al). 1986; 39:353-7

### Tertatolol

Reduction of beta-adrenergic receptors by tertatolol: An additional mechanism for beta-adrenergic blockade (De Blasi et al). 1986; 39:245-54

### Theobromine

Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrates of methylxanthines (Lelo et al). 1986; 39:54-9

### Theophylline

Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrates of methylxanthines (Lelo et al). 1986; 39:54-9

Cardiovascular effects of enprofylline and theophylline (Esquivel et al). 1986; 39:395-402

No "dose-dumping" with once-a-day Uniphyll (Goldenheim) (Letter); (Karim) (Reply). 1986; 39:598-9

Ranitidine at very large doses does not inhibit theophylline elimination (Kelly et al). 1986; 39:577-81

### Thiazide

The antihypertensive action of hydrochlorothiazide and renal prostacyclin (Wilson). 1986; 39:94-101

The cardiovascular risks of thiazide diuretics (Freis). 1986; 39:239-44 (Commentary)

Comparison of the effects of muzolimine and a fixed combination of diuretics in essential hypertension (Wicker and Clementy). 1986; 39:537-42

Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide (Hunninghake et al). 1986; 39:329-34

### Thromboxane A<sub>2</sub>

The pharmacokinetic and pharmacodynamic profiles of the thromboxane A<sub>2</sub> receptor blocker BM 13.177 (Patscheke et al). 1986; 39:145-50

### Tin-protoporphyrin

Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans (Anderson et al). 1986; 39:510-20

### Tipredane

Tipredane (USAN List No. 269). 1986; 39:173

### Tolerance

Tolerance and beta-adrenergic blocking activity of fleistolol, a short-acting beta blocker (Turlapaty et al). 1986; 39:543-9

### Total hip arthroplasty

Dihydroergotamine and mobilization after major orthopedic surgery (Duus et al). 1986; 39:342-4

### Training; see Education

**Transplantation**

Antipyrine kinetics in liver disease and liver transplantation (Mehta et al). 1986; 39:372-7

**Triamcinolone acetonide**

Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration (Derendorf et al). 1986; 39:313-7

**Triamcinolone hexacetonide**

Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration (Derendorf et al). 1986; 39:313-7

**Tripelennamine**

The pharmacokinetics of pentazocine and tripelennamine (Yeh et al). 1986; 39:669-76

**Tyramine**

Effect of diclofenase, a novel antidepressant, on peripheral adrenergic function (Gasić et al). 1986; 39:582-5

## U

**Uniphyll**

No "dose-dumping" with once-a-day Uniphyll (Goldenheim) (Letter); (Karim) (Reply). 1986; 39:598-9

**United Kingdom**

Clinical pharmacologists for the future in the United Kingdom (McDevitt). 1986; 39:459-61 (Symposium)

Current status of clinical pharmacology in the United Kingdom (Turner). 1986; 39:448-50 (Symposium)

The public need for clinical pharmacology in the United Kingdom (Dollery). 1986; 39:440-2 (Symposium)

**United States**

Clinical pharmacologists for the future in the United States (Oates). 1986; 39:462-5 (Symposium)

Current status of clinical pharmacology training in the United States (Peck and Crout). 1986; 39:451-8 (Symposium)

The public need for clinical pharmacology in the United States (Melmon). 1986; 39:443-7 (Symposium)

**United States Adopted Names Council**

USAN Council. 1986; 39:104-5, 173-4, 358-9, 433-4, 603-4, 705-6

**Urapidil**

Acute effects of increasing doses of urapidil in patients with hypertension (Culbertson et al). 1986; 39:690-6

USAN Council; see **United States Adopted Names Council**

## V

**Vancomycin**

Vancomycin elimination in patients with burn injury (Brater et al). 1986; 39:631-4

**Vasoconstrictor**

Prostaglandins and the control of the circulation (Nies). 1986; 39:481-8 (Commentary)

**Vasodilator**

The antihypertensive action of hydrochlorothiazide and renal prostacyclin (Wilson). 1986; 39:94-101

Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity (Möllerndorff et al). 1986; 39:677-82

Effect of cadralazine on brachial artery hemodynamics and forearm venous tone in essential hypertension (Bouthier et al). 1986; 39:82-8

Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. 1986; 39:43-8

Indomethacin attenuates the hypotensive action of hydralazine (Cinquemani and Liang). 1986; 39:564-70

Prostaglandins and the control of the circulation (Nies). 1986; 39:481-8 (Commentary)

**Ventricle**

Comparative effects of metoprolol and celiprolol on cardiac hemodynamics and left ventricular volume at rest and during exercise-induced angina (Silke et al). 1986; 39:5-14

## W

**Warfarin**

Role of alpha-1 acid glycoprotein, albumin, and nonesterified fatty acids in serum binding of apazone and warfarin (Urien et al). 1986; 39:683-9

The warfarin-sulfinpyrazone interaction: Stereochemical considerations (Toon et al). 1986; 39:15-24

**Weight**

Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modification (Weintraub et al). 1986; 39:501-9

**Workshop**

Present status and future directions of clinical pharmacology (Melmon and Turner). 1986; 39:435-6 (Symposium)

## X

**Xylofilocon A**

Xylofilocon A (USAN List No. 272). 1986; 39:604

**Xylose**

Xylose disposition as a function of age (Johnson et al). 1986; 39:697-702

## Z

**Zaltidine hydrochloride**

Zaltidine hydrochloride (USAN List No. 273). 1986; 39:706

**Zindotrine**

Zindotrine (USAN List No. 271). 1986; 39:434

